CoChat

Neuroprotective effects of testosterone treatment in men with multiple sclerosis

Open access
Kurth, Florian, Luders, Eileen, Sicotte, Nancy L., Gaser, Christian, Giesser, Barbara S., Swerdloff, Ronald S., Montag, Michael J., Voskuhl, Rhonda R., Mackenzie-Graham, Allan · 2014 · NeuroImage: Clinical
Cited by 131

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system. While current medication reduces relapses and inflammatory activity, it has only a modest effect on long-term disability and gray matter atrophy. Here, we have characterized the potential neuroprotective effects of testosterone on cerebral gray matter in a pilot clinical trial. Ten men with relapsing-remitting MS were included in this open-label phase II trial. Subjects were observed without treatment for 6 months, followed by testosterone treatment for another 12 months. Focal gray matter loss as a marker for neurodegeneration was assessed using voxel-based morphometry. During the non-treatment phase, significant voxel-wise gray matter decreases were widespread (p≤ 0.05 corrected). However, during testosterone treatment, gray matter loss was no longer evident. In fact, a significant gray matter increase in the right frontal cortex was observed (p≤ 0.05 corrected). These observations support the potential of testosterone treatment to stall (and perhaps even reverse) neurodegeneration associated with MS. Furthermore, they warrant the investigation of testosterone's neuroprotective effects in larger, placebo controlled MS trials as well as in other neurodegenerative diseases. This is the first report of gray matter increase as the result of treatment in MS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nicl.2014.03.001

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 131

Metadata

Authors
Kurth, F., Luders, E., Sicotte, N. L., Gaser, C., Giesser, B. S., Swerdloff, R. S., Montag, M. J., Voskuhl, R. R., & Mackenzie-Graham, A.
Venue
NeuroImage: Clinical
Publisher
Elsevier BV
Published
2014
Volume
4
Pages
454-460
ISSN
2213-1582 (ISSN-L)
OpenAlex
W2169730727
Cited by
131
References
8
FWCI
8.07
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuroprotective effects of testosterone treatment in men with multiple sclerosis. https://app.cochat.ai/papers/10.1016/j.nicl.2014.03.001
The paper
Kurth, F., Luders, E., Sicotte, N. L., Gaser, C., Giesser, B. S., Swerdloff, R. S., Montag, M. J., Voskuhl, R. R., & Mackenzie-Graham, A. (2014). Neuroprotective effects of testosterone treatment in men with multiple sclerosis. NeuroImage: Clinical. https://doi.org/10.1016/j.nicl.2014.03.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.